esigned to help address the challenges people living with a lung disease face every day. Leveraging the company's cutting edge science and leadership in chronic obstructive pulmonary disease (COPD), Boehringer Ingelheim is researching new treatment approaches where needs persist. It is the company's goal to make a difference in the lives of patients with COPD, asthma, lung cancer, idiopathic pulmonary fibrosis and other respiratory diseases.
About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
For more information please visit www.us.boehringer-ingelheim.com
Page: 1 2 3 4 5 6 7 Related medicine technology :1
|SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol for Maintenance Treatment of COPD2
. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease3
. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows4
. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate5
. Survey Shows eContent Critical to Corporate Strategies6
. New Forecast Shows Patient Monitoring Systems Market to Reach $18.9 billion by 20167
. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 20158
. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant9
. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy10
. Medical Device Recalls Soar During First Quarter, ExpertRECALL Index Shows11
. New Study Shows Long-Term Effects of Drug Prevention